634 related articles for article (PubMed ID: 25637943)
41. Use of toxicogenomics in drug safety evaluation: Current status and an industry perspective.
Vahle JL; Anderson U; Blomme EAG; Hoflack JC; Stiehl DP
Regul Toxicol Pharmacol; 2018 Jul; 96():18-29. PubMed ID: 29679677
[TBL] [Abstract][Full Text] [Related]
42. Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective.
Reynolds VL; Butler P; Abernathy MM; Aschenbrenner L; Best DD; Blank J; Crosby M; Custer L; Escobar PA; Kolaja K; Moggs J; Shuey D; Snyder C; Van Vleet T; Zhou J; Hart TK
Regul Toxicol Pharmacol; 2020 Nov; 117():104746. PubMed ID: 32911461
[TBL] [Abstract][Full Text] [Related]
43. Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules.
Luker T; Alcaraz L; Chohan KK; Blomberg N; Brown DS; Butlin RJ; Elebring T; Griffin AM; Guile S; St-Gallay S; Swahn BM; Swallow S; Waring MJ; Wenlock MC; Leeson PD
Bioorg Med Chem Lett; 2011 Oct; 21(19):5673-9. PubMed ID: 21852131
[TBL] [Abstract][Full Text] [Related]
44. Inclusion of Safety Pharmacology Endpoints in Repeat-Dose Toxicity Studies.
Redfern WS
Handb Exp Pharmacol; 2015; 229():353-81. PubMed ID: 26091647
[TBL] [Abstract][Full Text] [Related]
45. The evolving role of investigative toxicology in the pharmaceutical industry.
Pognan F; Beilmann M; Boonen HCM; Czich A; Dear G; Hewitt P; Mow T; Oinonen T; Roth A; Steger-Hartmann T; Valentin JP; Van Goethem F; Weaver RJ; Newham P
Nat Rev Drug Discov; 2023 Apr; 22(4):317-335. PubMed ID: 36781957
[TBL] [Abstract][Full Text] [Related]
46. Monitoring kidney safety in drug development: emerging technologies and their implications.
Dieterle F; Marrer E; Suzuki E; Grenet O; Cordier A; Vonderscher J
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):60-71. PubMed ID: 18175268
[TBL] [Abstract][Full Text] [Related]
47. Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials.
Sewell F; Chapman K; Baldrick P; Brewster D; Broadmeadow A; Brown P; Burns-Naas LA; Clarke J; Constan A; Couch J; Czupalla O; Danks A; DeGeorge J; de Haan L; Hettinger K; Hill M; Festag M; Jacobs A; Jacobson-Kram D; Kopytek S; Lorenz H; Moesgaard SG; Moore E; Pasanen M; Perry R; Ragan I; Robinson S; Schmitt PM; Short B; Lima BS; Smith D; Sparrow S; van Bekkum Y; Jones D
Regul Toxicol Pharmacol; 2014 Oct; 70(1):413-29. PubMed ID: 25078890
[TBL] [Abstract][Full Text] [Related]
48. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
49. Legacy data sharing to improve drug safety assessment: the eTOX project.
Sanz F; Pognan F; Steger-Hartmann T; Díaz C; ; Cases M; Pastor M; Marc P; Wichard J; Briggs K; Watson DK; Kleinöder T; Yang C; Amberg A; Beaumont M; Brookes AJ; Brunak S; Cronin MTD; Ecker GF; Escher S; Greene N; Guzmán A; Hersey A; Jacques P; Lammens L; Mestres J; Muster W; Northeved H; Pinches M; Saiz J; Sajot N; Valencia A; van der Lei J; Vermeulen NPE; Vock E; Wolber G; Zamora I
Nat Rev Drug Discov; 2017 Dec; 16(12):811-812. PubMed ID: 29026211
[TBL] [Abstract][Full Text] [Related]
50. Assessment of QT liabilities in drug development.
Arrigoni C; Crivori P
Cell Biol Toxicol; 2007 Jan; 23(1):1-13. PubMed ID: 17013551
[TBL] [Abstract][Full Text] [Related]
51. A global pharmaceutical company initiative: an evidence-based approach to define the upper limit of body weight loss in short term toxicity studies.
Chapman K; Sewell F; Allais L; Delongeas JL; Donald E; Festag M; Kervyn S; Ockert D; Nogues V; Palmer H; Popovic M; Roosen W; Schoenmakers A; Somers K; Stark C; Stei P; Robinson S
Regul Toxicol Pharmacol; 2013 Oct; 67(1):27-38. PubMed ID: 23602904
[TBL] [Abstract][Full Text] [Related]
52. Safety evaluation to support First-In-Man investigations II: toxicology studies.
Baldrick P
Regul Toxicol Pharmacol; 2008 Jul; 51(2):237-43. PubMed ID: 18501490
[TBL] [Abstract][Full Text] [Related]
53. Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2006; 54(2):94-8. PubMed ID: 16806993
[TBL] [Abstract][Full Text] [Related]
54. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of the relative performance of 12 urinary biomarkers for renal safety across 22 rat sensitivity and specificity studies.
Vlasakova K; Erdos Z; Troth SP; McNulty K; Chapeau-Campredon V; Mokrzycki N; Muniappa N; Gu YZ; Holder D; Bailey WJ; Sistare FD; Glaab WE
Toxicol Sci; 2014 Mar; 138(1):3-20. PubMed ID: 24361871
[TBL] [Abstract][Full Text] [Related]
56. Zebrafish assays as early safety pharmacology screens: paradigm shift or red herring?
Redfern WS; Waldron G; Winter MJ; Butler P; Holbrook M; Wallis R; Valentin JP
J Pharmacol Toxicol Methods; 2008; 58(2):110-7. PubMed ID: 18603451
[TBL] [Abstract][Full Text] [Related]
57. Impact of biomarker development on drug safety assessment.
Marrer E; Dieterle F
Toxicol Appl Pharmacol; 2010 Mar; 243(2):167-79. PubMed ID: 20036272
[TBL] [Abstract][Full Text] [Related]
58. Acute biomarker panel changes associated with amphotericin B nephrotoxicity in female Sprague-Dawley rats.
McDuffie JE; Lee S; Ma JY; Chen Y; Snook S
J Toxicol Sci; 2016; 41(4):459-68. PubMed ID: 27432232
[TBL] [Abstract][Full Text] [Related]
59. Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice.
Namdari R; Jones K; Chuang SS; Van Cruchten S; Dincer Z; Downes N; Mikkelsen LF; Harding J; Jäckel S; Jacobsen B; Kinyamu-Akunda J; Lortie A; Mhedhbi S; Mohr S; Schmitt MW; Prior H
Regul Toxicol Pharmacol; 2021 Nov; 126():105029. PubMed ID: 34455009
[TBL] [Abstract][Full Text] [Related]
60. The role for microRNAs in drug toxicity and in safety assessment.
Marrone AK; Beland FA; Pogribny IP
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):601-11. PubMed ID: 25739314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
